Overview of Current Research


The department has a strong history of extramural funding, especially in the areas of schizophrenia, depression, brain stimulation, and suicide.  We have received about $2,000,000 in direct costs support for our extramural research programs since fiscal year 2013, with the strongest support coming from the NIMH.

Active Extramural Grants in the Department, by topic:

Schizophrenia
A phase 2, Efficacy, Safety, and tolerability study of ALKS 3831 in schizophrenia with alcohol use disorder.
     Alkermes, Inc
     PI: Joseph McEvoy, M.D.
A phase 3 study to evaluate weight gain of ALKS 3831 compared to Olanzapine in adults with schizophrenia
     Alermes, Inc
     PI: Joseph McEvoy, M.D.
Double-blind placebo controlled study of adjunctive aripipazole for symptomatic hyperprolactinemia in premenopausal women with schizophrenia.
     University of Maryland
     PI: Joseph McEvoy, M.D.
A randomized, multi-site parallel-group, rater-blind study comparing response with aripiprazole once monthly and standard of care oral antipsychotics in non-adherent outpatients with schizophrenia identified using the brief adherence rating scale.
     Montana State University
     PI: Joseph McEvoy, M.D.
A cluster randomized, multi-center, parallel-group, rater-blind study comparing treatment with aripiprazole once monthly and treatment as usual on effectiveness in first episode and early phase illness in schizophrenia.
     Vanguard Research Group
     PI: Joseph McEvoy, M.D.
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/duinidine sulfate [Q]) as an adjunctive treatment for patients with residual schizophrenia.
     Avanir Pharmaceuticals, Inc.
     PI: Joseph McEvoy, M.D.
Clozapine for cannabis use disorder in schizophrenia.
     National Institute on Drug Abuse
     PI: Joseph McEvoy, M.D.
A randomized controlled trial of adjunctive tocilizumab in schizophrenia.
     NARSAD Independent Investigator Grant
     PI: Brian Miller, M.D., Ph.D., MPH
A randomized controlled trial of adjunctive siltuximab in schizophrenia.
     Stanley Medical Research Institute
     PI: Brian Miller, M.D., Ph.D., MPH
A potential state and relapse predictive marker in schizophrenia.
     National Institute of Mental Health
     PI: Brian Miller, M.D., Ph.D., MPH
BDNF/TrkB: a possible therapeutic target for schizophrenia.
      National Institute of Mental Health
      PI: Anilkumar Pillai, Ph.D
Paliperidone, mimicking paliperidone palmitate administration on brain BDNF: implications for relapse and neuroplasticity in schizophrenia.
     Ortho Mc-Neil Janssen Pharma
     PI: Anilkumar Pillai, Ph.D

Mood Disorders, Suicide and Sleep
Investigation of the Relationship between suicidal ideation and dysfunctional beliefs about sleep.
     PI: W. Vaughn McCall, M.D.
Rest-IT: Reducing suicidal ideation through treatment of insomnia.
     National Institute of Mental Health
     PI: W. Vaughn McCall, M.D.
Rest-IT: Reducing suicidal Ideation through treatment of nightmares.
     The American Foundation for Suicide Prevention
     PI: W. Vaughn McCall, M.D.
Regulation of TrkB signaling by 5-HT: role of transglutaminase 2
     National Institute of Mental Health
     PI: Anilkumar Pillai, Ph.D
Glucocorticoid-induced TrkB receptor regulation by ubiquitination
     National Institute of Mental Health
     PI: Anilkumar Pillai, Ph.D

Bipolar Disorder
5/5 Bipolar-Schizophrenia Network for intermediate phenotypes
     National Institute of Mental Health
     PI: Peter F. Buckley, M.D., Dean, Medical College of Georgia

Brain stimulation: ECT and rTMS
A randomized double-blind feasibility study comparing mood and cognitive outcomes for depressed patients treated with transcranial magnetic stimulation (TMS) combined with Lumosity cognitive exercises vs. computer game control task.
     PI: Peter B. Rosenquist, M.D.
The use of paired pulse TMS measures to assess drug effects on Neuronal Excitabiliy in Amyotrophic Lateral Sclerosis.
     PI: Peter B. Rosenquist, M.D.
Focal Electrically-Administered Seizure Therapy (FEAST): A preliminary study.
     MECTA Corporation
     PI: Peter B. Rosenquist, M.D. and W. Vaughn McCall, M.D.

Other
African Ancestry Genomic Psychiatry Cohort
     National Institute of Mental Health
     PI: Peter F. Buckley, M.D., Dean, Medical College of Georgia
Novel statistical approaches to analyzing actigraphy data.
     PI: W. Vaughn McCall, M.D.
A randomized, double-blind, placebo-controlled, fixed dose study of SD-809 (deutetrabenazine) for treatment of moderate to severe tardive dyskinesia.
     Auspex Pharmaceuticals, Inc.
     PI: Joseph McEvoy, M.D.
An open label, long-term safety study of SD-809 (deutetrabenazine) for treatment of moderate to severe tardive dyskinesia.
     Auspex Pharmaceuticals, Inc.
     PI: Joseph McEvoy, M.D.
Assessment and outcomes monitoring in psychiatric clinical practice.
     PI: Peter B. Rosenquist, M.D.